- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound plus biomarker finds early-stage ovarian cancer, saving lives
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
Ultrasound plus proteomic analysis of blood samples may help physicians identify early-stage ovarian cancer and save the lives of many women, according to researchers from the Mount Sinai School of Medicine and Vanderbilt University.
More than 21,500 women annually are diagnosed with the disease, 67% of them at an advanced stage. If ovarian cancer is detected at an early stage, survival is greater than 90%.
Contrast ultrasound may help confirm or eliminate the possibility that biomarkers can accurately detect early-stage ovarian cancer. Contrast agents may significantly improve the diagnostic ability of ultrasound to identify early microvascular changes known to be associated with earlystage ovarian cancer, said Dr. Arthur C. Fleischer, a coauthor of the study and a professor of radiology at Vanderbilt.
“Separately, proteomics and ultrasound are of limited value as early detection tools,” he said. “However, in combination, we will likely be able to shift from an era of diagnosing advanced stage ovarian cancer to that of early-stage disease, and save the lives of many women.”
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
